Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 2/20 | 0.34 |
| ▸ | OTC | P00480 | 1/20 | 0.31 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL28469088 | 0.98 | PRCP (0.35) | PRCPOTCDDAH1NOS3NOS1 | |
| Arginine SCHEMBL29206209 | 0.98 | PRCP (0.35) | PRCPOTCDDAH1NOS3NOS1 | |
| Arginine SCHEMBL6369693 | 0.96 | PRCP (0.37) | PRCPOTCDDAH1NOS3NOS1 | |
| Arginine SCHEMBL3405265 | 0.95 | PRCP (0.37) | PRCPOTCDDAH1NOS3NOS1 | |
| Arginine SCHEMBL22205220 | 0.95 | PRCP (0.37) | PRCPOTCDDAH1NOS3NOS1 | |
| Arginine SCHEMBL28901147 | 0.95 | PRCP (0.37) | PRCPOTCDDAH1NOS3NOS1 | |
| Arginine SCHEMBL6534744 | 0.95 | PRCP (0.37) | PRCPOTCDDAH1NOS3NOS1 | |
| Arginine SCHEMBL6535144 | 0.95 | PRCP (0.37) | PRCPOTCDDAH1NOS3NOS1 | |
| Arginine SCHEMBL25171512 | 0.95 | PRCP (0.33) | PRCP | |
| Arginine SCHEMBL29151521 | 0.95 | GSR (0.36) | PRCPOTC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1054677-B1 | COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES | CONNECTIVE TISSUE IMAGINEERING (US) | 2008-10-22 | — | — | EP | claimed |
| EP-1064010-B1 | PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME | CONNECTIVE TISSUE IMAGINEERING (US) | 2008-02-20 | — | — | EP | claimed |
| US-6777389-B1 | INHIBITING CUTANEOUS EFFECTS OF AGING | CONNECTIVE TISSUE IMAGINEERING LLC | 2004-08-17 | — | — | US | claimed |
| US-6069129-A | COMPOSITION FOR TREATING MAMMALIAN TISSUE COMPRISING PEPTIDE(S) OF GIVEN SEQUENCES; APPLYING TO HUMAN SKIN IN A COSMETIC OR THERAPEUTIC FORMULATION RESULTING IN ENHANCED ELASTICITY OF THE SKIN | MRS, LLC (US) | 2000-05-30 | — | — | US | claimed |
| EP-1998790-B1 | COMPOSITIONS CONTAINING PEPTIDES WITH NON-NATURAL AMINO ACIDS AND METHODS OF USE | AVON PROD INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-8551956-B2 | Compositions containing peptides with non-natural amino acids and methods of use | AVON PRODUCTS, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20090082252-A1 | Compositions Containing Peptides with Non-Natural Amino Acids and Methods of Use | AVON PRODUCTS INC. | 2009-03-26 | — | — | US | disclosed |
| EP-1054677-B1 | COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES | CONNECTIVE TISSUE IMAGINEERING (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1064010-B1 | PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME | CONNECTIVE TISSUE IMAGINEERING (US) | 2008-02-20 | — | — | EP | disclosed |
| EP-1392346-A4 | COMPOSITION AND METHOD FOR ENHANCING ELASTICITY OF TISSUE | CONNECTIVE TISSUE IMAGINEERING (US) | 2006-10-25 | — | — | EP | disclosed |
| EP-1054677-A4 | COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES | MRS LLC (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1392346-A2 | COMPOSITION AND METHOD FOR ENHANCING ELASTICITY OF TISSUE | Connective Tissue Imagineering LLC (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2001091700-A2 | COMPOSITION AND METHOD FOR ENHANCING ELASTICITY OF TISSUE | CONNECTIVE TISSUE IMAGINEERING LLC (US) | 2001-12-06 | — | — | WO | disclosed |
| EP-1054677-A1 | COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES | Mrs, Llc (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000028996-A1 | COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES | MRS, LLC (US) | 2000-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082252-A1 | Compositions Containing Peptides with Non-Natural Amino Acids and Methods of Use | CUTA, NGLY1, LNPEP | PRCP 184/4885OTC 1019/4885DDAH1 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.